# SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

> **NCT07132242** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 84 (estimated)

## Conditions studied

- Metastatic Breast Cancer With HER2 Positive

## Interventions

- **DRUG:** SHR-A1811 4.0mg/kg
- **DRUG:** Pyrotinib 240mg
- **DRUG:** SHR-A1811 4.8mg/kg
- **DRUG:** Pyrotinib 320mg

## Key facts

- **NCT ID:** NCT07132242
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132242, "SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07132242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*